Trial Now Recruiting: Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases (NCT06285539)
WHY IT MATTERS
If you have Behçet's disease, idiopathic inflammatory myopathy, or IgG4-related disease and are struggling with side effects from long-term steroid use, this Phase 2 trial is actively recruiting 60 patients and may offer access to a potentially safer treatment option.
Researchers are testing a new drug approach for three rare immune diseases: Behçet's disease, inflammatory myopathy (muscle inflammation), and IgG4-related disease. Currently, patients with these conditions take strong steroids and other immunosuppressive medications for long periods, which can cause serious side effects like infections. This trial is looking for a safer alternative treatment option.
NCT ID: NCT06285539 Status: RECRUITING Conditions: Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease Phase: PHASE2 Enrollment: 60 Sponsor: UMC Utrecht Summary: Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic inflammatory myopathy (IIM, also known as myositis) and IgG4-related disease (IgG4-RD) are treated with high-dosed glucocorticoids, methotrexate, azathioprine and mycophenolate mofetil, mostly for long periods of time with attendant risks of long-term toxicity, including infections. Therefore, there is an urgent need fo
YOU CAN ACT ON THIS
Contact UMC Utrecht or check clinicaltrials.gov (NCT06285539) immediately to see if you meet eligibility criteria, as this trial is currently recruiting participants.